Scholarlink

We presented a patient with history of autoimmune disease of the kidney which was reactivated after cancer diagnosis and exacerbated with immune checkpoint inhibitor (ICI) treatment. Patient’s reactivation of membranous nephropathy was due to a secondary cause which was the dual ICI therapy for his metastatic melanoma. Rituximab achieved excellent response and resolution of proteinuria after one cycle which was maintained on ICI for over 2 years with no exacerbation of his membranous nephropathy.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Membranous Nephropathy Post Immune Checkpoint Inhibitors

  • 章节

  • 发表日期：

    2025年

查看全文
  • Ala Abudayyeh,
  • Adi Diab,
  • Amanda Tchakarov

摘要

We presented a patient with history of autoimmune disease of the kidney which was reactivated after cancer diagnosis and exacerbated with immune checkpoint inhibitor (ICI) treatment. Patient’s reactivation of membranous nephropathy was due to a secondary cause which was the dual ICI therapy for his metastatic melanoma. Rituximab achieved excellent response and resolution of proteinuria after one cycle which was maintained on ICI for over 2 years with no exacerbation of his membranous nephropathy.